NCT05776134 2026-04-08
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Gilead Sciences
Available
Gilead Sciences
Novartis
Cogent Biosciences, Inc.
Karyopharm Therapeutics Inc
Autolus Limited
AbbVie
Phoenix Children's Hospital